NCT02922777已完成1 期
Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 2
- 主要终点
- Determine the maximum tolerated dose of BGB324 in combination with docetaxel
研究概览
简要总结
This study is being done to evaluate the safety of the investigational study drug, BGB324 when administered in combination with docetaxel, and to establish the maximum tolerated dose.
详细描述
Lung cancer remains the leading cause of cancer-related deaths worldwide with an estimated incidence of 1.6 million cases resulting in 1.4 million deaths in annually. Non-small-cell lung cancer (NSCLC) represents 80-85% of cases, and adenocarcinoma is the most common histology.2 The majority of NSCLC patients present with advanced or metastatic disease that is not amenable to surgical resection. Platinum-based combination chemotherapy has reached a therapeutic plateau with a median overall survival (OS) of 7.4 to 9.9 months.
BGB324 is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor that is over-expressed in many metastatic solid tumors and has been identified as a marker of a poor prognosis in patients with non-small cell lung cancer (NSCLC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A patient is eligible for the study if the following criteria are met:
- •Provision of written informed consent to participate in this investigational study
- •Histologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] Staging manual) NSCLC
- •Up to three previous lines of therapy, of which one must have been a platinum-based doublet therapy and no more than two were cytotoxic chemotherapy.
- •Radiographic disease recurrence or progression during or after the last line of chemotherapy
- •Patients with known activating EGFR mutations or ALK rearrangements should have progressed after appropriate targeted treatment in addition to progressing during or after platinum-based doublet chemotherapy
- •European Cooperative Oncology Group (ECOG) performance status 0 or 1
- •Age 18 years or older
- •Measurable or evaluable disease according to RECIST v1.1
- •Previously treated brain metastases (surgery and/or radiation therapy) are eligible, provided that patients are asymptomatic and not requiring corticosteroids
- •The following minimum intervals are required between prior treatment and initiation of study therapy:
- •Cytotoxic chemotherapy: 3 weeks Molecularly targeted therapy or immunotherapy: 2 weeks Conventional fractionated radiation therapy: 2 weeks Stereotactic radiation therapy: 1 week Major surgery: 3 weeks
- •Adequate hematologic function (absolute neutrophil count [ANC] ≥ 1500 cells/µL; hemoglobin ≥ 9 g/dL; platelets ≥ 100,000/µL
- •Adequate renal function (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation)
- •Adequate hepatic function: total bilirubin ≤ upper limit of normal [ULN], alanine aminotransferase [ALT] ≤ 1.5 x ULN, aspartate aminotransferase [AST] ≤ 1.5 x ULN). ALT and AST ≤ 5x ULN if documented liver metastases
- •Previous treatment-associated toxicities resolved to CTCAE grade ≤2 (except alopecia)
- •Adequate archival tissue (10-15 slides, or 5 slides with 3 sections per slide) for biomarker analysis
- •Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to taking their first dose of BGB
- •Male patients and female patients of reproductive potential must agree to practice highly effective methods of contraception (such as hormonal implants, combined oral contraceptives, injectable contraceptives, intrauterine device with hormone spirals, total sexual abstinence, vasectomy) throughout the study and for ≥3 months after the last dose of BGB
- •Female patients are considered NOT of childbearing potential if they have a history of surgical sterility, including tubal ligation, or evidence of post-menopausal status defined as any of the following:
- •Natural menopause with last menses >1 year ago
- •Radiation induced oophorectomy with last menses >1 year ago
- •Chemotherapy induced menopause with last menses >1 year ago
- •Exclusion Criteria
- •A patient is excluded from the study if any of the following criteria are met:
- •Pregnant or lactating
- •Abnormal left ventricular ejection fraction on echocardiography (less than the lower limit of normal for a patient of that age at the treating institution or <45%)
- •History of an ischemic cardiac event including myocardial infarction within 3 months of study entry
- •NSCLC with evidence of a centrally cavitating lesion
- •Peripheral neuropathy NCI CTCAE ≥Grade 2 at baseline
- •Pulmonary hemorrhage or hemoptysis > 2.5 mL blood within 6 weeks (or within 2 weeks if source definitively treated [eg, radiation therapy or bronchoscopic procedure])
- •Congestive cardiac failure of >Grade 2 severity according to the NYHA defined as symptomatic at less than ordinary levels of activity
- •Unstable cardiac disease, including unstable angina or unstable hypertension, as defined by the need for change in medication for lack of disease control within the last three months
- •History or presence of sustained bradycardia (less than or equal to 60 BPM) or history of symptomatic bradycardia, left bundle branch block, cardiac pacemaker or significant atrial tachyarrhythmias , as defined by the need for treatment
- •Previous treatment with docetaxel or an Axl inhibitor
- •Current treatment with agents that may prolong QT interval and may cause Torsade de Points which cannot be discontinued at least five half-lives prior to treatment. Please see Appendix J for list of relevant medications
- •Known family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy
- •Previous history of Grade 3 or worse drug-induced QTc prolongation requiring treatment withdrawal
- •Screening 12-lead ECG with a measurable QTc interval according to Fridericia's correction >450 ms
- •Ongoing infection requiring systemic treatment
- •Inability to tolerate oral medication
- •Impaired coagulation as evidenced by:
- •INR >1.5 times ULN, or
- •aPTT > 1.5 times ULN
- •Clinically active existing gastrointestinal disease affecting drug absorption, such as celiac disease or Crohn's disease
- •Previous bowel resection anticipated to affect drug absorption
- •Any evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol
- •Treatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index
- •Active, uncontrolled central nervous system (CNS) disease
- •Known active infection with human immunodeficiency virus (HIV), hepatitis B or C viruses (screening not required)
- 另有 1 项未显示
排除标准
- 未提供
研究组 & 干预措施
BGB324 in combination with docetaxel
Experimental
The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
干预措施: BGB324 (Drug)
BGB324 in combination with docetaxel
Experimental
The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
干预措施: Docetaxel (Drug)
结局指标
主要结局
Determine the maximum tolerated dose of BGB324 in combination with docetaxel
时间窗: 42 days or 2 cycles of 21 days
Determine and recommended the Phase 2 dose of BGB324 administered with the standard dose of docetaxel in patients in NSCLC by pharmacodynamics and pharmacokinetic assessments.
次要结局
未报告次要终点
研究者
David E Gerber
Professor, Internal Medicine
University of Texas Southwestern Medical Center
研究点 (2)
Loading locations...
相似试验
招募中
1 期
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsAdvanced Solid TumorHormone-receptor-positive Breast CancerHormone Receptor Positive Breast CarcinomaHormone Receptor Positive Malignant Neoplasm of BreastHER2-negative Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerAdvanced Breast CancerMetastatic Breast CancerNon-small Cell Lung CancerNCT06120283BeOne Medicines433
终止
1 期
Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory TumorsSolid TumorB-Raf Mutation-Related TumorsNCT04249843MapKure, LLC109
已完成
1 期
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaMelanomaNCT02872259Haukeland University Hospital74
已完成
3 期
Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen DeficiencyCongenital AfibrinogenemiaCongenital HypofibrinogenemiaNCT02065882Biotest67
已完成
1 期
A Study of PLX2853 in Advanced Malignancies.Uveal MelanomaNon-Hodgkin LymphomaAdvanced MalignanciesSolid TumorDiffuse Large B Cell LymphomaSmall Cell Lung CancerFollicular LymphomaOvarian Clear Cell CarcinomaNCT03297424Opna Bio LLC49